Condition: Locally Advanced or Metastatic Pancreatic Cancer With · Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
This study is a randomized, open-label, multicenter Phase II clinical trial designed to evaluate the Safety, Tolerability and Preliminary Efficacy of HRS-4642 Combination with Other Antitumor Therapies in Patients with Solid Tumors
This description comes directly from the study's public registry record.
Zengquan Gu · 0518-82342973 · zengquan.gu@hengrui.com
Always discuss trial participation with your own doctor first.
| Peking Union Medical College Hospital, Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07296341